NEW ORLEANS — Patients with wet age-related macular degeneration experienced a reduced treatment burden with sustained delivery sunitinib, according to a study presented here.
Veeral Sheth, MD, MBA, FACS, said GB-102 (sunitinib malate, Graybug Vision) is a pan-VEGF inhibitor.
“This is a platform that can be delivered with an intravitreal injection as a depot, which allows for sustained drug delivery,” he said at Retina Subspecialty Day at the American Academy of Ophthalmology meeting.
The phase 2b ALTISSIMO trial comprised 56 patients who had been diagnosed with wet AMD within